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Early and strong production of IFN-I by dendritic cells is important to control vesicular
stomatitis virus (VSV), however mechanisms which explain this cell-type specific innate
immune activation remain to be defined. Here, using a genome wide association study
(GWAS), we identified Integrin alpha-E (Itgae, CD103) as a new regulator of antiviral IFN-I
production in a mouse model of vesicular stomatitis virus (VSV) infection. CD103 was
specifically expressed by splenic conventional dendritic cells (cDCs) and limited IFN-I
production in these cells during VSV infection. Mechanistically, CD103 suppressed AKT
phosphorylation and mTOR activation in DCs. Deficiency in CD103 accelerated early IFN-I
in cDCs and prevented death in VSV infected animals. In conclusion, CD103 participates
in regulation of cDC specific IFN-I induction and thereby influences immune activation after
VSV infection.
Keywords: GWAS, genome wide association screen, Itgae, CD103, vesicular stomatitis virus, IFN-I, AKT, mTORINTRODUCTION
Type I interferon (IFN-I) is the strongest antiviral cytokine and prevents severe outcome of virus
infection (1, 2). IFN-I-dependent and –independent antiviral effector programs target several stages
of virus life cycle, including viral genome replication, transcription and translation (3). Most
important antiviral effector molecules are the myxovirus resistance (Mx) protein, which targets
incoming capsids prior to replication (4), 2,5-oligoadenylate synthetase (OAS) and RNase Lorg January 2021 | Volume 11 | Article 6078891
Duhan et al. Itgae Limits Virus-Induced IFN-I Productiondegrading viral RNA (5), while Protein kinase R (PKR) and
eukaryotic initiation factor 2 (eIF2a) limit translation of viral
proteins (6). In addition to its antiviral activity, IFN-I is involved
in several immune regulatory networks like innate immune
activation, NK cell activation, CD8 T cell priming, but also
immunosuppressive mechanisms i.e., interleukin-10 (IL-10)
and programmed cell death ligand 1 (PD-L1) expression (7, 8).
Enhanced and prolonged IFN-I activity results in over activation
of the immune system which may lead to severe autoimmune
disease (9).
During virus infection, signaling via pathogen recognition
receptors (PRRs), such as Toll-like receptors (TLRs) or retinoic
acid inducible gene I (RIG-I) induce IFN-I resulting in production
of IFN-I (10–12). Several cell types are able to produce IFN-I,
however specialized plasmacytoid dendritic cells (pDCs) produce
high amounts of IFN-I, and the IFN-I induction in these cells is
different from other innate cell types. In early endosomes of pDCs,
contact with viral RNA or DNA leads to activation of TLR7 and/or
TLR9, IRF7 activation and fast production of IFN-I (13).
Conventional dendritic cells (cDCs) are also equipped with
TLR7/9 and molecules of the IRF7 signaling cascade, however
compared to pDCs, cDCs produce reduced amounts of IFN-I
upon activation of TLR7/9 (14). Indeed, during virus infection,
cDCs mainly produce IFN-I after activation of RIG-I (15). One
explanation for this difference between cDCs and pDCs for IFN-I
production is signaling of FcϵR1g and DAP12, which in cDCs
inhibits IRF7 activation after TLR7/9 triggering (13). More
recently, the involvement of the PI3K-AKT pathway and mTOR
signaling was shown to be a major innate immune regulator,
which can regulate IFN-I induction and switches pDCs into high
IFN-I producer (16–18). Yet, mechanisms underlying a potential
differential AKT/mTOR activation linked to distinct abilities to
produce IFN-I in cDCs have to be defined.
The integrin alpha E (Itgae, aE, and CD103) interact with
Integrin beta 7 (ITGB7 and b7) to form heterodimer aEb7,
which is known to interact with E-cadherin (19). CD103
expression is mainly described on migrating and resident T
cells and DCs in many organs such as skin, gut, lung, spleen,
lymph nodes or tumors (19–21). The expression of CD103 is
restricted to type I dendritic cells (CD8a+ cDC1) and absent on
type II dendritic cells (CD11b+ cDC2). CD103+ cDC1 are
efficient in cross presentation by sampling antigens from
infected sites or tumors and migrate into the draining lymph
node to mount antigen-specific T cell response. CD103+ cDC1s
also cross-present self-antigens to maintain self-tolerance.
CD103+ DC1s are more crucial cell type for T cell immunity
than cDC2 which is necessary for host survival during
respiratory viral and bacterial infections (22). Previous reports
demonstrated that CD103+CD11b+ DCs respond strongly
during airway infections (23–25). Further intestinal CD103+
CD11b- dendritic cells are essential to prevent severe colitis
(26). This regulatory function of CD103+ CD11b- dendritic cells
was linked to their ability to induce IDO1 and interleukin-18 in
epithelial cells. CD103+ cDC1s support influenza replication as
compared to CD103- cDC2 in the lung and are associated with
dissemination of virus in the draining lymph node (27). The roleFrontiers in Immunology | www.frontiersin.org 2of CD103 molecules on DCs is only considered to define the
migratory cDC1. However, its direct role for regulating the anti-
viral immunity in DC1 remains unknown.
E-cadherins are surface adhesion molecules and can modulate
the PI3-kinase/Akt signaling cascade (28). In fact interaction of
E-cadherin with CD103 promotes anti-tumor CTL activity
(29, 30). In addition, the interaction of E-cadherin with CD103
can modulate several signaling pathways, including Wnt/b-
catenin, PI3K/Akt, Rho GTPase, and NF-kB signalling (31).
Such interaction will influence the function of monocytes,
macrophages and DCs. Whether such modulation can
influence the ability of DCs to produce IFN-I remains
mainly unknown.
Here, we performed a genome-wide association screen in
inbred mouse strains to determine mechanisms that regulate
early virus replication and IFN-I induction in the spleen. We
identified CD103 as blocker of IFN-I induction in cDCs.
Mechanistically CD103 limited AKT phosphorylation and
mTOR activation in cDCs.METHODS
Mice
Inbred mouse strains A/J (000646), AKR/J (000648), C3H/HeJ
(000659), DBA/1J (000670), C57BL/6J (000664), NZW/LacJ
(001058), FVB/NJ (001800), NOD/ShiLtJ (001976), CAST/EiJ
(000928), BALB/cJ (000651), 129S1/SvlmJ (002448), and BTBR
(002282) were purchased from Jackson. CBA/J, SJL/J and C57BL/
6NJ strains were bought from Charles River. 129S6 and C57BL/
6JBomTac inbred mouse strains were purchased from Taconic.
Itgae−/− mice (006144) were purchased from Jackson, bred and
maintained on C57BL/6J (000664) background, and littermate
wild type mice used as control for experiments. Ifnar−/−mice were
described previously (32) and maintained on C57BL/6
background. All animals were housed in single ventilated cages.
During survival experiments, the health status of the mice was
checked twice daily. Animal experiments were authorized by the
Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV)
Nordrhein-Westfalen and in accordance with the German law for
animal protection and/or according to institutional guidelines at
the Ontario Cancer Institute of the University Health Network.
Animals exhibiting severe symptoms of sickness or showing
substantial weight loss during infection were put to death and
were considered dead for statistical analysis.
GWAS and Genphen
The GWAS was performed for 4,000,000 SNPs found in different
inbred mouse strains (publicly available from http://mouse.cs.
ucla.edu/mousehapmap/full.html ), and the total amount of PFU
from spleen of 17 VSV infected inbred mouse lines (three
individuals per line) as a quantitative trait. First, the phenotype
was log10 transformed to make it conform to normality,
followed by an association test between each SNP and the
phenotype with EMMA as previously described (33, 34). The
strength of association was summarized with p-values.January 2021 | Volume 11 | Article 607889
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Variation Suite v8.7.2 (Golden Helix, Inc., Bozeman, MT, www.
goldenhelix.com).
The results obtained with EMMA were tested by a more
detailed analysis with genphen (freely available at https://www.
bioconductor.org/packages/genphen). To characterize the
strength of association between each SNP and the phenotype,
genphen computes several association metrics, including
classification accuracy (how well the alleles of a given SNP are
predicted from the quantitative trait), Cohen’s kappa (degree of
classification accuracy above expected), Cohen’s d (effect size
estimated with Bayesian inference model for testing the
difference of a continuous trait between two groups (alleles of
a SNP). The model was implemented in STAN (35), and is robust
against outliers. It enables the computation of complete
distribution of credible values for the Cohen’s d effect size. For
each metric, we estimated its mean, and 99% highest density
interval (HDI). The SNPs which scored high with respect to all
three metrics were considered as strong associations.
Virus, Plaque Assay, and Cell Line
VSV (Indiana strain, Mudd-Summers isolate), was originally
obtained from Prof. D. Kolakofsky (University of Geneva,
Switzerland). Virus was propagated on BHK-21 hamster
kidney fibroblasts at a multiplicity of infection 0.01 and was
plaqued onto Vero cells. VSV- EBOV was provided by Prof.
Marylyn M. Addo (co-author in this paper), grown on BHK-21
cells, and quantified using Vero cells.
Reagents and Antibodies
For flow cytometry and immunofluorescence assays, we used
antibodies specific for given antigens: monoclonal antibody to
VSV glycoprotein (Vi10, made in-house); CD103 (M290),
CD11b (M/70) and CD16/CD32 (2.4G2) were purchased from
BD Biosciences; CD103 (2E7), CD8a (53-6.7), CD11c (N418),
MHC Class II (I-A/I-E) (M5/114.15.2), F4/80 (BM8), CD115
(AFS98), Ly6C (HK1.4) and Ly6G (RB6-8C5) were purchased
from Thermo Fisher Scientific; IFNAR-1 (MAR1-5A3; BE0241)
and isotype control IgG1 k (MOPC-21; BE0083) were bought
from Bioxcell.
Reagents used for other analysis were bought from following
companies, recombinant mouse interferon alpha 4 (12115-1):
PBL assay science; AKT inhibitor, GSK2141795 (HY-15965):
MedChem Express; mTOR inhibitor, Rapamycin (1292): Tocris
and DAPI (4’,6-diamidino-2-phenylindole, Dilactate) 2 (D3571):
Thermo Fisher Scientific.
Surface Staining and Flow Cytometry
For surface staining, samples were incubated in antibody
solution prepared in FACS buffer for 30 min at 4°C. After
incubation samples were washed one time with FACS buffer
and processed for FACS analysis.
Cell Preparation and Staining for Dendritic
Cell Subsets Study and FACS Sorting
Spleens were injected with DMEM media containing 0.1 mg/ml
DNAse (grade II, Sigma Aldrich) and 1 mg/ml collagenase DFrontiers in Immunology | www.frontiersin.org 3(Sigma Aldrich) and incubated at 37°C for 40 min. After
incubation, spleens were minced with scissor, mixed using
pipette to obtain single cell suspension, and cells were washed
one time with FACS buffer. Cell suspension was passed through
100-mm strainer, and cells were treated with ACK buffer for 2
minutes to get rid of red blood cells. After one more washing
step, cells were processed for antibody staining.
Cells were first blocked for Fc receptors using anti-mouse
CD16/CD32 antibody (2.4G2) for 10 min at 4°C. Next, cells were
stained for biotin conjugated antibodies against lineage markers
CD3e (145-2C11), CD19 (6D5), N1.1 (PK136), and Ly6G (1A8)
for 15 minutes. For FACS sorting, in next step, cells were
incubated with anti-biotin micro beads (Miltenyi Biotec- 130-
090-485) and passed through column to get rid of undesired
cells. Unbounded cells were washed one time in MACS buffer
and incubated with a cocktail of antibodies against CD11c,
CD11b, B220 (RA3-6B2), CD8a, PDCA1 (eBio927), CD103,
and fluorescent labeled Streptavidin and DAPI for 20 min.
After one time washing with MACS buffer, cells were
processed for FACS sorting. For normal DC subset analysis,
samples were processed for antibodies staining without magnetic
sorting. FACS gating strategy for different DC populations is
shown in Figure S2A.Bone Marrow Derived Dendritic
Cell (BMDC)
Bone marrow cells were harvested from tibiae and femurs of mice,
erythrocytes were lysed with ACK lysis buffer, filtered and cultured
in VLE-DMEM media (FG1445; Merck Millipore) supplemented
with 5% culture supernatants containing murine GM-CSF
(prepared in house from X63-GM-CSF cell line culture), or 20%
of supernatant containing murine FLT3L (prepared in house from
CHO FLT3-L FLAG cell culture; CHO FLT3-L FLAG cell line was
kindly provided by Tim Sparwasser Institute of Infection
Immunology, TWINCORE, Hannover, Germany), heat
inactivated 10% fetal calf serum (10270; Gibco), 1% of penicillin,
streptomycin, L-glutamine solution (G6784 Sigma), and 0.1%
50mM beta mercaptoethanol (D4551, Sigma), which constitute a
complete media (CM) and cells were incubated at 37°C in a
humidified atmosphere with 5% CO2. Bone marrow cells seeded
with 3 × 106 cells per petri dish (58 cm2) in 10 ml of CM or in 24-
well plates with 2 × 105 cells/well in 1 ml CM. On day 3, extra CM
was added with volume equal to initial volume. On days 5–6, cells
were either harvested for seeding in 24 well plates or directly
treated in petri dishes.
Western Blot
BMDCs were washed 2x with PBS and cell lysate were
extracted with addition of hot SDS lysis buffer (1.1% SDS,
11% glycerol, and 0.1M Tris; pH 6.8) with 10% beta-
mercaptoethanol. Total cell extracts were examined with 10%
SDS polyacrylamide gel electrophoresis (SDS-PAGE) gels and
transferred onto Whatman nitrocellulose membranes (GE
Healthcare) according to standard techniques. Membranes were
blocked in 5% bovine serum albumin (PAA Laboratories), 1%
Tween-20 containing PBS for 1 hour at room temperature andJanuary 2021 | Volume 11 | Article 607889
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phospho-Akt (Ser473) (#4060), phospho-Akt (Thr308) (#13038),
Akt (Pan) (#4691), p-GSK-3b (Ser9) (#5558), GSK-3b (27C10)
(#9315), p-mTOR (Ser2481) (#2974), and pan-mTOR (7C10)
(#2983) which were bought from Cell Signaling Technology.
The following secondary antibodies were used, anti-mouse IgG
HRP linked antibody (NA931, GE Healthcare) or anti-rabbit IgG
HRP linked antibody (NA934, GE Healthcare) depending on host
for primary antibody. Signals were developed using ECL Western
Blotting Substrate (#32209, Thermo Fisher Scientific) or
SuperSignal West Femto Maximum Sensitivity Substrate
(#34096, Thermo Fisher Scientific). Signals were detected with
ChemiDoc imaging system (Biorad) and analysed with the Image
lab software (Biorad).
ELISA
Interferon a (IFN-a) enzyme-linked immunosorbent assay
(ELISA) was performed according to the manufacturer’s
protocol (PBL Interferon source).
Quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (15596, Thermo
Fisher Scientific). The cDNA was synthesized with the
QuantiTect reverse transcription kit (205313, Qiagen). Gene
expression assay was performed using Fast SYBR Green master
mix (Applied Biosystems) or TaqMan Fast Universal PCR
Master mix (Applied Biosystems) with LightCycler 480
instrument (Roche). For qRT-PCR, the following primers from
Qiagen were used: Interferon beta-1 (QT00249662), Interferon
alpha-4 (QT01774353), Interferon alpha-2 (QT00253092), Itgae
(QT00102914) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (QT01658692). For analysis, the expression levels of
all target genes were normalized against GAPDH (DCt). Gene
expression values were calculated with the DDCt method.
Statistical Analysis
Data are expressed as means ± SEM. Student’s t-test was used to
detect statistically significant differences between groups.
Statistical analysis for survival between two groups was
analyzed by log-rank (Mantel-Cox) test. The level of statistical
significance was set at P < 0.05.RESULTS
GWAS Screen Reveals CD103 as
Regulator of Viral Replication
To determine new host factors that modulate virus replication,
we performed a genome-wide association study (GWAS) in a
mouse model of vesicular stomatitis virus infection (VSV). We
selected 17 different commercially available inbred mouse lines,
which have been genotyped for single nucleotide polymorphisms
(SNPs) and are distinguished by overall 1,846,759 mutations in
total of 41,017 genes (36). All 17 mouse strains were infected
with 2x108 PFU of VSV and after 7 hours we determined
infectious replicating viral particles in the spleen. We foundFrontiers in Immunology | www.frontiersin.org 4very diverse replication of VSV within different mouse strains
(Figure 1A), suggesting that different variants in these strains
influence replication of VSV and/or innate immune activation.
EMMA-analysis of publicly available 4 million SNPs revealed
that among 207,760 SNPs located in exons of coding genes, 5 top
SNPs in the genes Ckap2l, Sirpa, Lypla2, Itgae and Ablim1
correlated significantly with VSV replication (Figures 1B and
Table S1). To test this first statistical survey using an
independent approach, we applied the genphen method
(described in material and methods), which classifies all SNPs
to their corresponding phenotype. Using this approach, we
found SNPs in 28 known different genes which could explain
the differences in VSV replication (Figure 1C and Table S2).
Among these 28 genes, 2 genes, Itgae and Sirpa had a missense
variant (Figure 1C). Because these two genes were also among
the top hits of the EMMA analysis, we considered them as most
probable for explaining the differences found in the different
inbred mouse strains. To validate the direct role of Sirpa and
Itgae on VSV replication, we infected Sirpa−/− and Itgae−/− mice
with VSV and analyzed viral replication after 8 hours. Viral titers
were not affected in Sirpa−/− mice, but were reduced in spleen
and liver of Itgae−/− mice (Figure 1D). From these results we
concluded that the missense SNP rs26903412 in the Integrin
alpha-E (Itgae, CD103) gene on chromosome 11 position
73,115,640 (Supplementary Figure 1) could explain the
different VSV replication in the different mouse strains and,
more important, that CD103 is one important regulator, which
influence early VSV propagation.
CD103 Limits Early Interferon
Production and Enhances
Susceptibility to Virus Infection
Next, we aimed to analyze the mechanisms leading to different
viral replication in the absence of CD103. We considered that
early innate immune activation and induction of antiviral
programs was one likely explanation for differences in viral
replication. Indeed, CD103 was mainly expressed in
conventional DCs (Figure 2A), suggesting this cell type was
mainly responsible for different VSV replication in Itgae−/− mice
and inbred mice with the missense SNPs. Since fast innate
immune activation and production of IFN-I is most effective to
block VSV replication, we considered that IFN-I response may
be modulated by CD103. During VSV infection first pDCs
produce IFN-I which is hardly systemically detectable, but still
important for viral control (37). In a second line of defense,
conventional dendritic cells produce systemically measurable
IFN-I (37). To get insights on the role of CD103 on IFN-I
induction we first analyzed systemic IFN-alpha in WT and
Itgae−/− mice. Itgae−/− mice showed increased systemic IFN-
alpha already 4 hours after infection (Figure 2B). At later time
points IFN-alpha levels were similar or even enhanced in WT
mice (Figure 2B). This suggests that either other innate immune
cells such as pDCs produce higher amounts 4 hours after VSV
infection, or that in addition to pDCs, conventional DCs produce
IFN-I already 4 hours after VSV infection. To get insights we
infected WT and Itgae−/− mice with VSV and then sorted splenicJanuary 2021 | Volume 11 | Article 607889
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IFN-I. After 4 hours of VSV infection, pDCs of WT versus
Itgae−/− mice showed similar levels of IFN-I mRNA expression
(Figure 2C). Therefore, we conclude, that IFN-I mRNA
expression by pDCs is not significantly influenced by CD103
expression (Figure 2C). In contrast cDC1s and cDC2s of WT
versus Itgae−/− mice showed enhanced levels of IFN-I mRNA
expression (Figure 2C), which suggests that absence of CD103
enhances the capacity of these cell type to produce IFN-I, albeit
the overall increase of IFN-I mRNA expression in pDCs
compared to cDC1 and cDC2 was much higher in infected
versus uninfected mice. CD103 expression on cDC2 was absent
in naïve state (Figure 2A), however it was induced upon VSV
infection (Supplementary Figure 2B) which explains the
enhanced IFN-I response in cDC2s after VSV infection
(Figure 2C). The enhanced IFN-I induction in cDCs could not
be explained by enhanced replication of VSV in these cells, as
VSV replication was reduced in Itgae−/− cells (Figure 2D andFrontiers in Immunology | www.frontiersin.org 5Supplementary Figure 2C). Next, we analyzed whether the
different IFN-I induction and viral replication impacted on
virus control. Survival experiments revealed enhanced survival
of Itgae−/− mice (Figure 2E), suggesting an important role of
CD103 during VSV infection. Together these data show that lack
of CD103 enhanced IFN-I production in conventional dendritic
cells, which impacts on outcome of the infection.
CD103 Limits IFN-I Response in Bone
Marrow Derived Dendritic Cells
To validate our hypothesis that CD103 regulates IFN-I response
in cDCs, we generated dendritic cells by culturing bone marrow
cells (BMDCs) in presence of GMCSF which are most close to
cDCs (38). BMDCs expressed CD103 (Figure 3A and
Supplementary Figure 3A). To test their ability to produce
IFN-I in response to VSV, we infected BMDC cultures with
VSV and measured IFN-I in RT-PCR. In line with the data
from ex vivo analyzed cDCs, we found elevated IFN-I inductionA B
DC
FIGURE 1 | GWAS screen reveals CD103 as regulator of viral replication. (A) Virus titers in spleens of different inbred mouse strains which were intravenously (i.v)
infected with 2x108 PFU of VSV and analyzed after 8 h (n = 3). (B) Manhattan plot showing the distribution of SNPs present in each chromosome in exon regions on
x-axis with its associated p-values on y-axis of the EMMA analysis based on the virus titers measured in (A). Five most significantly regulated genes are highlighted
with red arrows. (C) Plot representing distribution of reference SNPs based on classification accuracy (x-axis), Bayesian Cohen’s d (y-axis) and Cohen’s kappa
(colour code) of the genphen analysis of the data in (A). The list of all SNPs present in the top refSNP which is represented by dotted circle is within Table S2. The
table depicted at top of (C), shows the top SNPs located in the exon regions. (D) Viral titers from spleen and liver of WT or Sirpa−/− or Itgae−/− mice after i.v. infection
with 2x108 PFU of VSV, measured after 8h (n = 4 for WT and Sirpa−/−; n = 10 for WT and Itgae−/−, pooled from two independent experiments). Horizontal dotted
lines represent the detection threshold (D). Data are shown as mean ± SEM. ***P < 0.001; ****P < 0.0001 (Student’s t-test).January 2021 | Volume 11 | Article 607889
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enhanced IFN-I induction could not be explained by enhanced
viral replication, as VSV replication was strongly reduced in
Itgae−/− BMDCs (Figure 3C and Supplementary Figure 3B).Frontiers in Immunology | www.frontiersin.org 6Also, production of infectious virus was strongly reduced in
in Itgae−/− BMDC cultures (Figure 3D). Culture of bone
marrow (BM) cells in presence of GMCSF result in a mixture




FIGURE 2 | CD103 limits early Interferon production and enhances susceptibility to virus infection. (A) Representative FACS plots for CD103 expression on different
splenic immune cells of naïve WT and Itgae−/− mice (n = 4). Values in the plots represents the frequency of cells within CD103 positive bar. (B) Total IFN-a in serum of
WT and Itgae−/− mice, which were infected with 2x108 PFU of VSV and at various time points as indicated (n = 3-10). (C) Gene expression data determined by RT-PCR
in various FACS sorted DC subtypes from spleens of WT and Itgae−/− mice which were left untreated or were infected i.v with 2x109 PFU of VSV for 2h or 4h (n = 3).
(D) Representative FACS plots showing staining for VSV glycoprotein (GP) on splenic DC subtypes of naïve WT, and WT, Itgae−/− and IFNAR−/− mice which were infected
i.v with 2x109 PFU of VSV for 4h (n = 3). (E) Survival of WT and Itgae−/− mice, which were infected with 2x107 PFU of VSV (n = 14-16). Data are shown as mean ± SEM
or Kaplan Meier graph. n.s. not significant; *P < 0.05; **P < 0.01; ***P < 0.001; (Student’s t-test for B and C, and Mentel-Cox survival test for C).January 2021 | Volume 11 | Article 607889





FIGURE 3 | CD103 limits IFN-I response in bone marrow derived dendritic cells. (A) Representative FACS plot showing CD103 expression on MHCII+CD11c+ cells
from naïve BMDC culture from WT or Itgae−/− mice (n = 3). Values in the plots represents the frequency of cells within CD103 positive bar. (B) Expression of Ifna4
and Ifnb1 determined by RT-PCR in WT and Itgae−/− BMDC which were left untreated or were treated with VSV (MOI = 1 for 3 h, n = 3). (C) Representative FACS
plot showing VSV-GP staining from naïve or VSV treated (MOI-0.01 for 24h) BMDC generated from WT or Itgae−/− mice (n = 3). (D, E) BMDC generated from WT
and Itgae−/− mice (n = 6) incubated with VSV-WT (MOI = 1, D) or VSV- EBOV (MOI = 1, E) and after 1h media was replaced with virus free fresh complete media and
virus titers measured in supernatant at indicated time points. (F) Virus titers in supernatants of WT and Itgae−/− BMDC, which were treated with anti-IFNAR antibody
(40µg/ml) or isotype control antibody (40µg/ml), measured after infection with VSV (MOI = 0.001, n = 6). (G) Virus titers in supernatants of WT and Itgae−/− BMDC,
which were treated with IFNa4 (100U/ml), measured after infection with VSV (MOI = 0.01, n = 6). Data are shown as mean ± SEM. n.s. not significant; *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001 (Student’s t-test).Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6078897
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cDCs, we cultured BM cells in presence of GMCSF and FLT3L
which mainly derive cDCs differentiation (Supplementary
Figure 3C). We could find similar suppression pattern for
virus replication in Itgae−/− BMDCs from theses cultures
(Supplementary Figure 3D). Further, we excluded that
enhanced virus replication in presence of CD103 was due to a
direct interaction of VSV-GP with CD103, as the recently
licensed Ebola vaccine VSV-EBOV showed similarly reduced
replication in Itgae−/− BMDCs cultures (Figure 3E). Rather, we
considered that the reduced VSV replication in BMDC cultures
was due to enhanced IFN-I induction in cultures of Itgae−/−
BMDCs. Indeed, blockage of interferon-a/b receptor (IFNAR)
enhanced replication of VSV in Itgae−/− BMDCs to WT levels
after 72h of infection, although in earlier time points CD103
still accelerated VSV propagation (Figure 3F). Vice versa
treatment with IFN-a4 limited VSV replication in WT
BMDCs to levels of Itgae−/− BMDCs (Figure 3G). In
conclusion we found that intrinsic expression of CD103 on
dendritic cells limited induction of IFN-I and thereby was
responsible at least partially for accelerated VSV replication.CD103 Modulates AKT Activation and
mTOR Signaling
In a next step, we addressed the molecular mechanisms leading
to high IFN-I production in Itgae−/− BMDCs. IFN-I is produced
upon activation of pattern recognition receptors which recognize
viral nucleic acids and positively regulated by various molecules
such as AKT/mTOR (18, 40), glycogen synthase kinase 3
(GSK3), NF-kB, histone deacetylase 3 (HDAC3) and tyrosine-
protein phosphatase non-receptor type 22 (PTPN22) (41). To get
insights we generated BMDCs from WT and Itgae−/− mice and
analyzed for known pathways that regulate IFN-I signaling.
Interestingly we found increased phosphorylation of AKT in
Itgae−/− BMDCs (Figure 4A). Next, we analyzed for GSK-3b
which is a prime target of AKT in downstream signaling and get
degraded upon phosphorylation. We detected higher
phosphorylation of GSK-3b and reduced total GSK-3b protein
level (Figure 4A). One downstream target of AKT is mTOR (42).
mTOR was shown to be one major contributor to IFN-I
production in pDC (18). Indeed, phosphorylated mTOR was
overexpressed in Itgae−/− BMDCs when compared to WT
(Figure 4B). In line with these findings, inhibition of AKT and
mTOR signaling enhanced VSV replication in Itgae−/− BMDCs,
but not in WT BMDCs (Figures 4C, D), suggesting that
enhanced AKT/mTOR activation is one crucial parameter
underlying the reduced virus replication observed upon CD103
deficiency. Further to confirm the direct role of mTOR inhibition
with rapamycin in regulation of IFN-I response, we treated
BMDCs with rapamycin and analyzed early IFN-I response
upon VSV infection (Figure 4E). As expected, rapamycin
treatment inhibited the virus induced early IFN-I response in
Itgae−/− BMDCs similar to the level of WT BMDCs. These
findings suggest that CD103 inhibits IFN-I response in AKT/
mTOR dependent manner which promotes virus replication
in DCs.Frontiers in Immunology | www.frontiersin.org 8DISCUSSION
Here, we found, using a mouse model of vesicular stomatitis
virus (VSV) infection, that Integrin alpha-E (Itgae, CD103)
modulated IFN-I induction in cDCs. Mechanistically CD103
limited AKT signaling and mTOR activation, one pathway which
is essential for early IFN-I response. In vivo, lack of CD103
resulted in enhanced early IFN-I production and improved virus
control and survival during VSV infection.
pDCs are specialized IFN-I producing cells. Especially during
VSV infection, production of IFN-I by pDCs a few hours after
infection is essential for virus control (37, 43). Conventional
dendritic cells (cDCs) are also equipped with TLR7. However, in
contrast to pDCs, cDCs produce hardly any IFN-I after uptake of
VSV into TLR7 containing endosomes, and only extensive
replication of VSV in cDCs leads to RIG-I activation and IFN-
I induction (37, 44, 45). Our data indicate that expression of
CD103 is one factor, which explains this difference between
pDCs and cDCs. Lack of CD103 in cDCs accelerated the
production of IFN-I. The enhanced IFN-I production in
CD103-deficient cDCs could not be explained by extensive
replication of VSV in cDCs, as we found limited replication of
VSV in CD103-deficient cDCs. From our data it remains
unexplained whether the enhanced IFN-I production during
VSV infection was specific for either TLR7 or RIG-I. As we
found increased mTOR signaling in CD103-deficient cDCs, we
consider that both pathways might be affected by CD103. cDC1
are known to express higher level of TLR3 than TLR7. For this
study we used VSV, which is a single stranded RNA virus. VSV
can activate several innate receptors including TLR4, TLR7, and
RIG-I. Therefore, we cannot conclude on the specific role of
CD103 in TLR3 signaling. Further studies have to be done to
clarify this point.
We consider it likely that the enhanced IFN-I induction is not
specific for VSV. This would suggest that cDCs are hyper-
reactive in terms of IFN-I production, which might accelerate
autoimmune disease. Indeed, it was reported previously that
mice lacking CD103 start to develop spontaneous inflammatory
skin disease after 6 months of their age on 129/Sv x BALB/c
background (46). Whether this autoimmunity is linked to over-
activated cDCs and is dependent on IFN-I remains unknown so
far. Further studies have to be undertaken to address the possible
role of CD103, IFN-I signaling and autoimmunity.
We found that high CD103 expression in the spleen is mainly
restricted to naïve CD8+ T cells and CD8a+ DC (cDC1). CD103
expression on cDC1 modulated IFN-I and promoted virus
replication. We have not identified how CD103 influences
IFN-I induction and whether certain ligands modulate IFN-I
response in cDCs. E-cadherin is one interaction partner of
CD103 which can modulate functional activity in CD103+
CD8 T cells (30). Therefore, we could consider that the
interaction of E-cadherin with CD103 influences IFN-I
induction in DCs.
Van Prooyen et al. published that during fungal infection
CD103+ conventional DCs are the major producer of IFN-I and
IFN-gamma in the lungs of wild-type mice (25). While these data
may look contradictory to our work, the authors did not directlyJanuary 2021 | Volume 11 | Article 607889
Duhan et al. Itgae Limits Virus-Induced IFN-I Productionanalyze the role of CD103 in IFN-I expression, but rather used
expression of CD103 to identify the specific dendritic subset. We
could speculate that either, these cell types have limited interaction
with E-cadherin or that absence of the CD103 signaling in their
system might still enhance the production of IFN-I.
We found that CD103 affected also replication of VSV-EBOV
which might have an impact on the outcome of vaccination with
VSV-EBOV, which was recently licensed as the first Ebola
vaccine and is currently administered large scale in the
ongoing Ebola outbreak in the Democratic Republic of Congo.
In humans SNPs in the CD103 genes are known, howeverFrontiers in Immunology | www.frontiersin.org 9whether these modulate the interaction of CD103 with E-
cadherin and thereby modulate IFN-I responses remains to be
studied. If indeed SNPs in CD103 would modulate the binding to
E-cadherin such SNPs would accelerate IFN-I response and
adaptive immune activation after vaccination. Because VSV-
EBOV can persist in joints after vaccination (47), and therefore
can lead to side effects, such SNPs could correlate with reduced
incidence of side effects. More data have to be generated to shed
light in this interaction.
In conclusion we found that CD103 blocks IFN-I induction in




FIGURE 4 | CD103 modulates AKT activation and mTOR signaling. (A) Representative western blots for naïve WT and Itgae−/− BMDC detected with antibodies to
phospho-AKT (Thr308), phospho-AKT (Ser473), AKT (pan), phospho-GSK-3b (Ser9), GSK-3b (pan) and GAPDH. Graphs show the quantifications for p-AKT
(Thr308), p-AKT (Ser473), and phospho-GSK-3b (Ser9) from naïve WT and Itgae−/− BMDCs (n = 3). (B) Representative western blots for naïve WT and Itgae−/−
BMDC detected with antibodies to p-mTOR (Ser2481) and mTOR (pan). Graph shows the quantifications for p-mTOR (Ser2481) from naïve WT and Itgae−/− BMDCs
(n = 3). (C) Virus titers at different time intervals after virus infection in supernatants of WT and Itgae−/− BMDC, which were treated with or without the AKT inhibitor
GSK2141795 (4500 nM) for 24h and infection with VSV (MOI = 0.01, n = 6). Data shown is pooled from two independent experiments. (D) Virus titers at different
time intervals after virus infection in supernatants of WT and Itgae−/− BMDCs, which were treated with or without the mTOR inhibitor Rapamycin (200 nM) for 24h
and infection with VSV (MOI = 0.01, n = 3). (E) Expression of Ifnb1 determined by RT-PCR in WT and Itgae−/− BMDC which were treated with or without rapamycin
(200nM) for 24h and infected with VSV or left without infection for 3h (MOI = 1). Data are shown as mean ± SEM. n.s. not significant; *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001 (Student’s t-test).January 2021 | Volume 11 | Article 607889
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SUPPLEMENTARY FIGURE 1 | Association between mouse genotype and
splenic virus replication of inbred mouse strains. Table showing the details for a top
SNP in the Itgae gene associated with virus replication correspondence to its
genotype and average virus particles (log10 transformed, n = 3) per spleen in
different strains. ‘A’ represents Adenine and ‘G’ represents Guanine.
SUPPLEMENTARY FIGURE 2 | CD103 inhibits IFN-I response in cDCs.
(A) Representative gating strategy for DC subsets in the spleen of WT mouse.
(B) Gene expression data determined by RT-PCR in various FACS sorted DC
subtypes from spleens of WT and Itgae−/− mice which were left untreated or were
infected i.v with 2x109 PFU of VSV for 2h or 4h (n = 3). (C) Graphs showing the
staining for VSV glycoprotein (GP) on splenic DC subtypes from spleens of naïve
WT, and WT, Itgae−/− and IFNAR−/− mice which were infected i.v with 2x109 PFU of
VSV for 4h (n = 3-5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01
(Student’s t-test).
SUPPLEMENTARY FIGURE 3 | CD103 inhibits IFN-I response in BMDCs.
BMDCs derived from GMCSF (A, B) or GMCSF plus FLT3L (C, D) cultures were
kept without infection for control or infected with VSV. (A) FACS plot showing the
frequency of CD103 cells in MHC-II+ cells from naïve BMDC (n = 3). (B) Frequency
of VSV-GP staining from VSV treated (MOI-0.01 for 24h) BMDC generated fromWT
or Itgae−/− mice (n = 3). (C) FACS plot showing the frequency of CD103+ cells in
total MHC-II+ cells from naïve BMDC (n = 3). (D) Representative FACS plot and
graph showing VSV-GP staining from naïve or VSV treated (MOI-0.01 for 24h)
BMDC generated fromWT or Itgae−/−mice (n = 3). Data are shown as mean ± SEM.
*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001 (Student’s t test).
SUPPLEMENTARY TABLE 1 | List of SNPs associated with virus replication
analyzed by EMMA. This table includes all SNPs present in known genes along with
different variants with a cut off p-value (-log10) = 3 which are associated with virus
replication in different inbred mouse lines from Figure 1B.
SUPPLEMENTARY TABLE 2 | List of SNPs present in top reference SNP
analyzed by genphen. This table includes all SNPs present in top refSNP which is
denoted by dotted circle in Figure 1C.REFERENCES
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